东北制药(000597) - 2017 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2017 was ¥1,450,839,471.51, representing a 16.14% increase compared to ¥1,249,229,225.39 in the same period last year[8] - Net profit attributable to shareholders was ¥10,875,440.21, a significant turnaround from a loss of ¥4,179,474.29, marking a 360.21% increase[8] - The net profit after deducting non-recurring gains and losses was ¥7,165,269.69, compared to a loss of ¥7,131,081.27, reflecting a 200.48% improvement[8] - The total profit for the period was 15.82 million CNY, an increase of 204.72% compared to the previous period, primarily due to increased revenue and gross profit, along with reduced asset impairment losses[6] - Basic earnings per share were ¥0.02, up 300.00% from a loss of ¥0.01 per share in the same period last year[8] Cash Flow - The net cash flow from operating activities reached ¥107,142,592.72, a 319.51% increase from a negative cash flow of ¥48,810,273.02 in the previous year[8] - Cash received from sales of goods and services amounted to 1,224.27 million CNY, an increase of 63.51% compared to the previous period, mainly due to an increase in cash collections from matured sales notes[6] - Cash paid for purchasing goods and accepting services was 681.43 million CNY, an increase of 40.89% compared to the previous period, driven by increased sales and corresponding raw material purchases[6] - Cash received from investment was 16 million CNY, a decrease of 84% compared to the previous period, mainly due to fewer financial products sold[6] - Cash received from other operating activities was 14.46 million CNY, a decrease of 51.81% compared to the previous period, mainly due to a reduction in deferred income and receivables[6] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,962,173,506.43, a 1.76% increase from ¥9,789,980,904.20 at the end of the previous year[8] - The net assets attributable to shareholders were ¥2,325,208,469.10, reflecting a slight increase of 0.46% from ¥2,314,478,440.16[8] - The ending balance of accounts receivable notes was 238.27 million CNY, a decrease of 33.24% compared to the beginning of the year, mainly due to the maturity of certain receivable notes[6] - The ending balance of employee compensation payable was 4.91 million CNY, a decrease of 38.59% compared to the beginning of the year, primarily due to payments made for unpaid employee compensation from the previous year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,156[11] Non-Recurring Gains - The company reported non-recurring gains totaling ¥3,710,170.52, primarily from government subsidies and asset disposals[9] Tax and Regulatory Information - The company's tax and additional fees for the period were 19.43 million CNY, an increase of 159.65% compared to the same period last year, due to changes in tax regulations[6] - There were no violations of external guarantees during the reporting period[20] Future Outlook - The company expects significant changes in net profit compared to the same period last year, but specific forecasts are not applicable at this time[17] Return on Equity - The weighted average return on equity improved to 0.47%, compared to -0.18% in the same period last year, representing a 361.11% increase[8]